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LETTERS TO THE EDITOR
Paradoxical Sinus Deceleration During
Dobutamine Stress Echocardiography
In the April 1997 issue of the Journal, Attenhofer et al. (1) observed
paradoxical sinus deceleration in 14 (8%) of 181 patients during
dobutamine stress echocardiography. Significant coronary artery dis-
ease was present in eight patients and absent in the remaining six.
Activation of the Bezold-Jarish reflex, promoting reflex bradycardia,
vasodilation and hypotension, is suggested as a probable mechanism.
In our experience, hypotension (systolic blood pressure decrease
.30 mm Hg) without simultaneous deceleration of heart rate occurred
in 8% of patients during dobutamine stress echocardiography (2).
However, of 114 patients who also underwent coronary angiography
for assessment of coronary artery lesions, heart rate increased in 12 of
the 15 patients given a bolus of 1 mg of atropine, but only 2 patients
achieved 85% of the maximal heart rate, and heart rate remained
almost unchanged in 3 (2 without beta-adrenergic drugs). These three
patients had significant coronary artery lesions (percent diameter
stenosis .70%). Given the difficulty in achieving 85% of the maximal
heart rate even in patients given atropine, heart rate changes as an
indirect sign of atherosclerotic coronary artery disease were evaluated.
We found that a heart rate ,112 beats/min at the end of dobutamine
stress echocardiography without treatment with beta-blockers showed
a sensitivity of 65%, a specificity of 83% and a diagnostic accuracy of
73% for the diagnosis of coronary artery disease. In addition, heart
rate ,94 beats/min independently of the treatment received and
abnormalities of myocardial contractility (multivariate analysis)
showed a sensitivity of 69% and a specificity of 70% for the diagnosis
of multivessel coronary artery disease (3).
In the study of Attenhofer et al. (1), although the number of
patients treated with beta-blockers is not mentioned, seven of eight
patients with significant coronary artery disease showed a heart rate
,112 beats/min, and three of five patients with two- or three-vessel
coronary disease showed a heart rate ,94 beats/min. In the six patients
without significant coronary artery disease, dobutamine stress echo-
cardiography revealed myocardial contractility abnormalities in two,
with atherosclerotic coronary lesions of percent diameter stenosis
,50%. However, it is possible that a more accurate measurement of
atherosclerotic lesions with the use of calipers could have resulted in a
decrease in the number of false positive results.
Heart rate response to dobutamine stress echocardiography may
include three possibilities: 1) acceleration up to 85% of maximal heart
rate; 2) initial acceleration, followed by deceleration and hypotension
through a vagal mechanism; and 3) limited increase in heart rate in
patients with or without treatment with beta-blockers. In experimental
studies, Vatner et al. (4) showed that in the absence of coronary artery
disease, dobutamine increases heart rate in ;20% and cardiac con-
tractility in 125%, whereas in the presence of coronary artery occlu-
sion, there was an increase in heart rate and contractility of 15% and
32%, respectively, as opposed to exercise, in which case, heart rate
increased by 102% and contractility decreased by 63%. Dobutamine
directly stimulates adenosine triphosphate (ATP)- and cyclic adeno-
sine monophosphate (cAMP)-dependent beta-adrenergic receptors,
resulting in an increase in cardiac contractility and chronotropism.
Stimulation of cAMP-independent alpha-adrenergic receptors causes
an increase in cardiac contractility. In the initial phase of ischemia,
there is a decrease in ATP production, which may induce a lower
response to stimulation of beta-adrenergic receptors and, conse-
quently, a lower chronotropic response (5,6) without alteration of
cardiac contractility because these events occur when there is an
important increase in heart rate (7).
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Reply
Cladellas et al. report their interesting observation that a maximal
heart rate ,112 beats/min with dobutamine stress echocardiography in
the absence of beta-blocker medications indicates significant coronary
artery disease with a diagnostic accuracy of 73%. Cladellas et al.
believe that the insufficient heart rate increase during high dose
dobutamine infusion results from a decrease in adenosine triphosphate
production due to myocardial ischemia. However, in 17% of their
patients, an insufficient heart increase to ,112 beats/min was seen in
the absence of coronary artery disease. Thus, in their experience, an
attenuated chronotropic response cannot always be attributed to
myocardial ischemia.
In the experimental study by Vatner et al. (1), the absolute heart
rate increase with dobutamine was modest but similar with and without
ischemia (16 and 15 beats/min, respectively), although the baseline
heart rate was higher in dogs with ischemia. Thus, despite myocardial
ischemia, the chronotropic response to dobutamine was intact. The
duration of infusion of 40 mg/kg per min dobutamine was brief, 1 to
3 min, and differentiates that experimental work from the more
prolonged infusion typically used with dobutamine stress echocardiog-
raphy and probably accounts for the much smaller increment in heart
rate than is usually observed during dobutamine stress echocardiogra-
phy.
Our work (2) concerned the paradoxical heart rate decrease
occasionally observed during dobutamine stress echocardiography.
Thus, in all patients a higher heart rate was obtained during dobut-
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amine infusion before the decrease. By contrast, the observations of
Cladellas et al. concern patients who failed to achieve an adequate
heart rate response; it is not clear whether heart rate decrease
occurred in any patient. As we reported, only 1 of 14 patients with
paradoxical sinus deceleration was taking beta-blockers. We men-
tioned in our report that all our patients fasted for at least 3 h before
dobutamine stress echocardiography; mild hypovolemia may have
facilitated the occurrence of the vasodepressor response.
In our conclusions, we reported that paradoxical sinus deceleration
was most often seen in patients with coronary artery disease, but in
14% of our patients with heart rate decrease, there were no angio-
graphic, echocardiographic, electrocardiographic or clinical signs of
coronary artery disease. Sinus deceleration was often accompanied by
a decrease in blood pressure, nausea and chest pain. We believe that
sinus deceleration during dobutamine stress echocardiography is typ-
ically mediated by the Bezold-Jarisch reflex and is most commonly
seen in the presence of ischemia but may occur in its absence.
The echocardiographic signs of myocardial ischemia may be subtle
if heart rate is not increased and can be best appreciated by continuous
echocardiographic surveillance. Atropine is effective in increasing
heart rate in patients with paradoxical bradycardia and is recom-
mended in those with no manifestations of ischemia.
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F-18 FDG Uptake in Transplanted Heart
In their recent report, Rechavia et al. (1) concluded that a threefold
increase in the uptake of the glucose tracer analogue fluorine-18
2-deoxy-2-fluoroglucose (F-18 FDG) in transplanted hearts reflects a
preference for glucose as a substrate. The authors further concluded
that this preference for glucose may be due either to inefficient
utilization of glucose by the transplanted heart or to the influence of
circulating catecholamines.
This observation can be explained entirely by a change in the
relation between F-18 FDG and glucose. The latter is commonly
referred to as the “lumped constant” (LC) (2). This ratio between
tracer (F-18 FDG) and tracee (glucose) reflects the kinetic differences
between glucose and deoxyglucose transport and phosphorylation.
Most studies have used a fixed value of 0.67 to quantitate glucose
uptake from the F-18 FDG tracings (3–5), but we (6,7) and others (8)
have recently observed in the isolated working heart that the LC is
subject to significant variability, depending on the metabolic environ-
ment. Insulin and competing substrates to glucose cause a decrease in
the LC (6–8), whereas epinephrine and ischemia can cause an increase
in the LC (unpublished observations). An increase in the LC causes an
overestimation of glucose uptake, whereas a decrease in the LC results
in an underestimation of glucose uptake.
Thus, considering the results of Rechavia et al. (1) in light of the
experimental findings (6–8), the concept of an increased LC in the
transplanted hearts is in order. Such an increase would lead to the over-
estimation of glucose uptake. This effect may artificially introduce and
accentuate otherwise minor differences in glucose uptake. The possi-
bility of increased catecholamine sensitivity and the possible presence
of chronic “demand ischemia” in transplanted hearts would argue in
favor of this hypothesis.
A practical solution to this problem would be to determine the LC
individually for every study from the time-activity curves of F-18 FDG
accumulation (9). The results presented by Rechavia et al. (1) are
undoubtedly interesting, but we caution against drawing any conclu-
sions regarding the quantitation of glucose uptake or metabolism in
transplanted human heart.
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Reply
In their comment on the report by Rechavia et al. (1), Doenst and
Taegtmeyer make several important statements about the lumped
constant (LC) for fluorine-18 2-fluoro-2-deoxy-D-glucose (F-18 FDG)
and how changes in this variable would reflect on the quantitative
assessment of myocardial glucose utilization with this method. They
also surmize how the LC may differ between fasting conditions in
normal subjects and in transplant recipients.
We agree with the view that it is important to develop an
understanding of how the kinetics of F-18 FDG and glucose differ
under varying pathophysiologic conditions in humans, but the absence
of appropriate and unequivocal data means that predictions of how the
LC might change clinically are still clearly speculative.
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